OpenLB
Open Library of Bioscience
Advanced Search
Cancer medicine
Apr, 2025;14 (7): e70840.

Dose-Volume Constraints for Thoracic, Abdominal, and Pelvic Carbon Ion Radiotherapy: A Literature Review.

Maria Varnava, Mutsumi Tashiro, Masahiko Okamoto, Ken Ando, Nobutero Kubo, Hidemasa Kawamura, Masahiro Onishi, Kei Shibuya, Takuya Kumazawa, Takeru Ohtaka, Tatsuya Ohno
Author Information
  1. Maria Varnava: Gunma University Heavy Ion Medical Center, Maebashi, Gunma, Japan. ORCID
  2. Mutsumi Tashiro: Gunma University Heavy Ion Medical Center, Maebashi, Gunma, Japan. ORCID
  3. Masahiko Okamoto: Gunma University Heavy Ion Medical Center, Maebashi, Gunma, Japan.
  4. Ken Ando: Gunma University Heavy Ion Medical Center, Maebashi, Gunma, Japan.
  5. Nobutero Kubo: Gunma University Heavy Ion Medical Center, Maebashi, Gunma, Japan.
  6. Hidemasa Kawamura: Gunma University Heavy Ion Medical Center, Maebashi, Gunma, Japan. ORCID
  7. Masahiro Onishi: Gunma University Heavy Ion Medical Center, Maebashi, Gunma, Japan.
  8. Kei Shibuya: Gunma University Heavy Ion Medical Center, Maebashi, Gunma, Japan.
  9. Takuya Kumazawa: Gunma University Heavy Ion Medical Center, Maebashi, Gunma, Japan.
  10. Takeru Ohtaka: Gunma University Heavy Ion Medical Center, Maebashi, Gunma, Japan.
  11. Tatsuya Ohno: Gunma University Heavy Ion Medical Center, Maebashi, Gunma, Japan.
PMID: 40156204 DOI: 10.1002/cam4.70840

Abstract

BACKGROUND: Applying dose-volume constraints is extremely important in ensuring the safe use of radiotherapy. However, constraints for carbon ion radiotherapy (CIRT) have not been established yet. This review aims to summarize dose-volume constraints for thoracic, abdominal, and pelvic CIRT that have been identified through previous research based on the Japanese models for relative biological effectiveness (RBE).
RESULTS: Constraints are reported for the lungs, liver, stomach, gastrointestinal tract, rectum, sigmoid, bladder, nerves, rib, femoral head, sacrum, and skin. The constraints are classified into hard and soft to aid in determining whether priority should be given to the target coverage or organ-at-risk (OAR) sparing during treatment planning.
CONCLUSIONS: Further research is necessary to verify the applicability of the reported constraints and to identify constraints for the OARs that have not been investigated yet.

Keywords

abdominal cancer carbon ion radiotherapy dose–volume constraints organs at risk pelvic cancer thoracic cancer

References

  1. Oncotarget. 2018 May 01;9(33):22976-22985 [PMID: 29796166]
  2. Front Oncol. 2021 Sep 21;11:715025 [PMID: 34621672]
  3. Radiother Oncol. 2019 Dec;141:227-233 [PMID: 31522881]
  4. Acta Oncol. 2016;55(2):163-6 [PMID: 26399488]
  5. Cancers (Basel). 2019 Dec 21;12(1): [PMID: 31877802]
  6. Radiother Oncol. 2012 Dec;105(3):273-82 [PMID: 23245644]
  7. Lancet Oncol. 2015 Feb;16(2):e93-e100 [PMID: 25638685]
  8. PLoS One. 2019 May 28;14(5):e0216809 [PMID: 31136589]
  9. Int J Mol Sci. 2024 Nov 30;25(23): [PMID: 39684602]
  10. Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S3-9 [PMID: 20171515]
  11. Front Oncol. 2023 Feb 16;13:1054693 [PMID: 36874141]
  12. In Vivo. 2022 Sep-Oct;36(5):2473-2480 [PMID: 36099090]
  13. Int J Radiat Oncol Biol Phys. 2024 Mar 1;118(3):639-649 [PMID: 37924986]
  14. Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):388-97 [PMID: 16626894]
  15. Radiother Oncol. 2010 Apr;95(1):60-5 [PMID: 19767117]
  16. Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S94-100 [PMID: 20171524]
  17. Phys Med Biol. 2010 Nov 21;55(22):6721-37 [PMID: 21030747]
  18. Radiother Oncol. 2016 Aug;120(2):307-12 [PMID: 27394694]
  19. Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):322-327 [PMID: 27084649]
  20. Radiat Oncol. 2021 Apr 13;16(1):72 [PMID: 33849589]
  21. Radiat Oncol. 2020 Dec 10;15(1):277 [PMID: 33302998]
  22. Radiat Oncol. 2024 Apr 22;19(1):51 [PMID: 38649902]
  23. Cancers (Basel). 2021 Jun 28;13(13): [PMID: 34203485]
  24. Front Oncol. 2022 Mar 02;12:829502 [PMID: 35311095]
  25. J Appl Clin Med Phys. 2024 Jul;25(7):e14321 [PMID: 38436509]
  26. Radiother Oncol. 2016 Jul;120(1):140-4 [PMID: 27178145]
  27. Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):498-504 [PMID: 26883565]
  28. Radiat Res. 1997 Jan;147(1):78-85 [PMID: 8989373]
  29. Radiat Oncol. 2017 Sep 2;12(1):144 [PMID: 28865463]
  30. Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):854-60 [PMID: 22483698]
  31. J Radiat Res. 2022 Mar 17;63(2):296-302 [PMID: 35152291]
  32. World J Radiol. 2024 Jul 28;16(7):256-264 [PMID: 39086610]
  33. Cancers (Basel). 2018 Mar 06;10(3): [PMID: 29509684]
  34. Front Med (Lausanne). 2022 Mar 25;9:858929 [PMID: 35402457]
  35. Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22 [PMID: 2032882]
  36. Med Phys. 2018 Nov;45(11):e1096-e1110 [PMID: 30421806]
  37. Anticancer Res. 2020 Jan;40(1):379-386 [PMID: 31892590]
  38. Anticancer Res. 2022 Jul;42(7):3701-3706 [PMID: 35790269]
  39. Radiat Oncol. 2018 Jun 25;13(1):119 [PMID: 29941040]
  40. J Radiat Res. 2024 Jul 22;65(4):512-522 [PMID: 38842119]
  41. Phys Med. 2021 Oct;90:6-12 [PMID: 34521017]
  42. Cancer. 2009 Mar 15;115(6):1348-55 [PMID: 19156905]
  43. Radiother Oncol. 2022 Dec;177:33-39 [PMID: 36252637]
  44. Adv Radiat Oncol. 2025 Feb 07;10(3):101711 [PMID: 40007614]
  45. Front Oncol. 2019 Aug 07;9:731 [PMID: 31448233]
  46. Radiother Oncol. 2016 Jan;118(1):136-40 [PMID: 26700600]
  47. Cancers (Basel). 2017 Jun 09;9(6): [PMID: 28598362]
  48. Radiother Oncol. 2019 Nov;140:175-181 [PMID: 31310888]
  49. Int J Radiat Oncol Biol Phys. 2003 Mar 15;55(4):861-6 [PMID: 12605963]
  50. Radiat Oncol. 2017 Nov 22;12(1):185 [PMID: 29166945]
  51. Int J Part Ther. 2021 Jun 25;8(1):25-35 [PMID: 34285933]
  52. Lancet Oncol. 2007 Nov;8(11):1007-17 [PMID: 17976611]
  53. Cancers (Basel). 2018 Sep 18;10(9): [PMID: 30231543]
  54. Semin Radiat Oncol. 2024 Apr;34(2):207-217 [PMID: 38508785]
  55. Phys Med Biol. 2012 Nov 21;57(22):7543-54 [PMID: 23104051]
  56. Gynecol Oncol. 2014 Jan;132(1):87-92 [PMID: 24183732]
  57. Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):1084-91 [PMID: 16979840]
  58. Cancer Med. 2023 Apr;12(7):8267-8277 [PMID: 36799088]
  59. Int Immunopharmacol. 2024 Jan 5;126:111263 [PMID: 38000232]
  60. Int J Radiat Oncol Biol Phys. 1999 Apr 1;44(1):201-10 [PMID: 10219815]
  61. Front Oncol. 2020 Nov 24;10:531344 [PMID: 33330020]
  62. Cancer. 2020 Sep 15;126(18):4188-4196 [PMID: 32658315]
  63. Radiother Oncol. 2022 Oct;175:73-78 [PMID: 35952977]
  64. Radiother Oncol. 2020 Mar;144:30-36 [PMID: 31710941]
  65. Surg Today. 2006;36(8):692-700 [PMID: 16865512]
  66. Radiat Oncol. 2017 May 30;12(1):91 [PMID: 28558766]
  67. Cell Death Discov. 2021 Sep 16;7(1):244 [PMID: 34531376]

MeSH Term

Humans
Heavy Ion Radiotherapy
Radiotherapy Dosage
Organs at Risk
Radiotherapy Planning, Computer-Assisted
Pelvic Neoplasms
Abdominal Neoplasms
Pelvis
Thoracic Neoplasms
Relative Biological Effectiveness
Journal Article Review

Word Cloud

Created with Highcharts 10.0.0constraintsradiotherapycancerdose-volumecarbonionCIRTyetthoracicabdominalpelvicresearchConstraintsreportedBACKGROUND:ApplyingextremelyimportantensuringsafeuseHoweverestablishedreviewaimssummarizeidentifiedpreviousbasedJapanesemodelsrelativebiologicaleffectivenessRBERESULTS:lungsliverstomachgastrointestinaltractrectumsigmoidbladdernervesribfemoralheadsacrumskinclassifiedhardsoftaiddeterminingwhetherprioritygiventargetcoverageorgan-at-riskOARsparingtreatmentplanningCONCLUSIONS:necessaryverifyapplicabilityidentifyOARsinvestigatedDose-VolumeThoracicAbdominalPelvicCarbonIonRadiotherapy:LiteratureReviewdose–volumeorgansrisk

Similar Articles

Cited By